<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="99850"><DrugName>arsenic trioxide (oral, acute promyelocytic leukemia), Orsenix Holdings</DrugName><DrugNamesKey><Name id="42756757">arsenic trioxide</Name></DrugNamesKey><DrugSynonyms><Name><Value>arsenic trioxide</Value><Types><Type>USAN</Type></Types></Name><Name><Value>arsenic trioxide (oral, acute promyelocytic leukemia), Orsenix Holdings</Value></Name><Name><Value>ORH-2014</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>1327-53-3</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1116159">Orsenix Holdings BV</CompanyOriginator><CompaniesPrimary><Company id="1116159">Orsenix Holdings BV</Company></CompaniesPrimary><CrossReferences><SourceEntity id="1116159" type="Company"><TargetEntity id="5047444000" type="organizationId">Orsenix Holdings BV</TargetEntity></SourceEntity><SourceEntity id="1731" type="ciIndication"><TargetEntity id="D015470" type="MeSH"/><TargetEntity id="519" type="ORPHANET"/><TargetEntity id="-1550871001" type="omicsDisease"/><TargetEntity id="686" type="siCondition"/></SourceEntity><SourceEntity id="1732" type="ciIndication"><TargetEntity id="C92.4" type="ICD10"/><TargetEntity id="205" type="ICD9"/><TargetEntity id="10001019" type="MEDDRA"/><TargetEntity id="D015473" type="MeSH"/><TargetEntity id="520" type="ORPHANET"/><TargetEntity id="688" type="siCondition"/></SourceEntity><SourceEntity id="2054" type="ciIndication"><TargetEntity id="10066476" type="MEDDRA"/><TargetEntity id="D019337" type="MeSH"/><TargetEntity id="-105358819" type="omicsDisease"/><TargetEntity id="1328" type="siCondition"/></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C1">Phase 1 Clinical</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="1731">Acute myelogenous leukemia</Indication><Indication id="2054">Hematological neoplasm</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="1732">Acute promyelocytic leukemia</Indication></IndicationsSecondary><ActionsSecondary><Action id="1545">Anticancer</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="586">Capsule formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2019-06-25T08:46:50.000Z</LastModificationDate><ChangeDateLast>2019-06-27T00:00:00.000Z</ChangeDateLast><AddedDate>2015-11-17T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1116159" linkType="Company"&gt;Orsenix Holdings&lt;/ulink&gt; is developing ORH-2014, an oral capsule formulation of arsenic trioxide, for the potential treatment of hematological cancers, including  acute promyelocytic leukemia (APL)  and acute myeloid leukemia (AML) [&lt;ulink linkID="1712786" linkType="Reference"&gt;1712786&lt;/ulink&gt;],  [&lt;ulink linkID="1904967" linkType="Reference"&gt;1904967&lt;/ulink&gt;], [&lt;ulink linkID="1738218" linkType="Reference"&gt;1738218&lt;/ulink&gt;]. In December 2016, a phase I  study was initiated in patients with advanced hematological cancers [&lt;ulink linkID="1904967" linkType="Reference"&gt;1904967&lt;/ulink&gt;]; in June 2018, data were presented [&lt;ulink linkID="2045635" linkType="Reference"&gt;2045635&lt;/ulink&gt;], [&lt;ulink linkID="2045477" linkType="Reference"&gt;2045477&lt;/ulink&gt;]; in December 2018, the trial was ongoing [&lt;ulink linkID="1904967" linkType="Reference"&gt;1904967&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In November 2015, the US FDA granted the product Orphan designation for the treatment of APL [&lt;ulink linkID="1712786" linkType="Reference"&gt;1712786&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In January 2016, the EMA's COMP recommended arsenic trioxide for Orphan Drug status for the treatment of AML [&lt;ulink linkID="1730761" linkType="Reference"&gt;1730761&lt;/ulink&gt;]; in February 2016, the EC granted the drug Orphan status  [&lt;ulink linkID="1738218" linkType="Reference"&gt;1738218&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In December 2016, a three-part open-label, non-randomized, non-placebo-controlled dose escalation phase I study  (&lt;ulink linkID="287752" linkType="Protocol"&gt;NCT03048344&lt;/ulink&gt;; ORH2014-001) in patients with hematological disorders  was initiated in the US to evaluate the safety and tolerability of ORH-2014. At that time, the trial was expected to completed in March 2021 [&lt;ulink linkID="1904967" linkType="Reference"&gt;1904967&lt;/ulink&gt;]. In June 2018, data were presented at the  23rd EHA Annual Congress in Stockholm, Sweden. Cmax and AUC0-24 values of total arsenic after 15 days were 64.5 ng/ml (43.2%) and 1340 h*ng/ml (43.9%), respectively. Plasma arsenic exposure (AUC0-24) after 15 days for 10mg qd was similar to the levels observed for an iv preparation of arsenic (Trisenox; 0.15 mg/kg qd) at day 8. The drug was well tolerated with no significant DLTs, renal or hepatic function abnormalities, or blood count abnormalities. Most adverse events were low grade and considered related to underlying disease. One patient with MDS was reported as being in complete remission of the bone marrow at both 2 and 5 months after initiation of treatment [&lt;ulink linkID="2045635" linkType="Reference"&gt;2045635&lt;/ulink&gt;], [&lt;ulink linkID="2045477" linkType="Reference"&gt;2045477&lt;/ulink&gt;]. In December 2018, the trial was ongoing [&lt;ulink linkID="1904967" linkType="Reference"&gt;1904967&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In June 2018, preclinical data were presented at the  23rd EHA Annual Congress in Stockholm, Sweden, showing that ORH-2014  oral doses had similar pharmacokinetics to iv arsenic trioxide in dogs [&lt;ulink linkID="2045635" linkType="Reference"&gt;2045635&lt;/ulink&gt;], [&lt;ulink linkID="2045477" linkType="Reference"&gt;2045477&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1116159">Orsenix Holdings BV</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="2054">Hematological neoplasm</Indication><StatusDate>2016-12-02T00:00:00.000Z</StatusDate><Source id="1904967" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1116159">Orsenix Holdings BV</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2016-01-27T00:00:00.000Z</StatusDate><Source id="1730761" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1116159">Orsenix Holdings BV</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1732">Acute promyelocytic leukemia</Indication><StatusDate>2015-11-02T00:00:00.000Z</StatusDate><Source id="1712786" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1116159">Orsenix Holdings BV</OwnerCompany><Country id="EU">EU</Country><Indication id="1731">Acute myelogenous leukemia</Indication><AwardedIndication>Treatment of acute myeloid leukaemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2016-02-17T00:00:00.000Z</MileStoneDate><Source id="1738218" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1116159">Orsenix Holdings BV</OwnerCompany><Country id="US">US</Country><Indication id="1732">Acute promyelocytic leukemia</Indication><AwardedIndication>Treatment of acute promyelocytic leukemia.</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2015-11-02T00:00:00.000Z</MileStoneDate><Source id="1712786" type="CORPORATE"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1116159">Orsenix Holdings BV</OwnerCompany><Country id="EU">EU</Country><Indication id="1731">Acute myelogenous leukemia</Indication><AwardedIndication>Treatment of acute myeloid leukaemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2001-01-21T00:00:00.000Z</MileStoneDate><Source id="1730761" type="PR"/></Row></RegulatoryDesignationStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>O1[As]2O[As]3O[As]1O[As](O2)O3</Smiles></StructureSmiles><PatentFamilies><PatentFamily id="3262873" number="WO-2016123603" title="High surface-area lyophilized compositions comprising arsenic for oral administration in patients"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Orsenix Holdings BV" id="1116159"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>